Research updates, April 30

Posted by

  • The National Institutes of Health (NIH) is making data from its RECOVER initiative available to other researchers studying Long Covid, the agency announced in a press release last week. This dataset includes anonymized, secure medical records from more than 14,000 people participating in the initiative’s observational research — including those living with Long Covid and those participating as controls — spanning 92,000 study visits between October 2021 and September 2023. Researchers can request access to the dataset through a NIH portal. The new data availability follows past criticism from scientists and patient-advocates that RECOVER has failed to transparently share its progress and collaborate with the broader Long Covid research community.
  • A new study in The Lancet Infectious Diseases found a significant correlation between persistent SARS-CoV-2 virus and Long Covid symptoms. Scientists discovered viral RNA in the solid tissue of multiple organs, as well as subgenomic RNA, which may indicate active replicating virus. “Patients with higher virus copy numbers had a higher likelihood of developing Long Covid symptoms,” the study’s authors wrote. Read more about the study on Long Covid Weekly.
  • The company BioVie was recently given a $13.1 million grant from the Department of Defense to study the drug Bezisterim for Long Covid. Bezisterim is an anti-inflammatory and insulin sensitizer that has also been tested for Alzheimer’s disease and traumatic brain injury. The grant will fund a three-month-long clinical trial of the drug with around 200 participants. 

Subscribe to our weekly newsletter

* indicates required

Leave a Reply

Blog at WordPress.com.

Discover more from The Sick Times

Subscribe now to keep reading and get access to the full archive.

Continue reading